---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000097"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:54:39.155525+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Keros licenses elritercept to Takeda for $200M upfront; milestones up to $1.1B

## Summary
- Upfront payment of $200M; eligible for up to $370M in development/commercial milestones and $740M in sales milestones.
- Tiered royalties on net sales in Territory (ex-China) from low double-digits to high teens, subject to reductions.
- Elritercept in Phase 2 for MDS and myelofibrosis; Phase 3 RENEW trial for MDS to begin enrollment soon.
- Keros expects upfront proceeds to extend cash runway into Q4 2028, supporting cibotercept and KER-065 programs.
- Agreement effective subject to HSR Act clearance.

## SEC filing metadata
- accession: 0001664710-24-000097
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000097/0001664710-24-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000097/kros-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000097
- JSON: https://secwatch.observer/filing/0001664710-24-000097.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.